Korea Botox Rivalry To Intensify After Meditoxin Measures
Punitive Steps To Impact Market
As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.
You may also be interested in...
Medytox Faces Botulinum Approval Cancellation Over Data Issues
Leading South Korean botulinum toxin company Medytox is facing substantial business risk as its Meditoxin product is suspended amid test result manipulation investigations.
Orange Grove CEO: Korean Opportunities A Priority In Global Expansion
US-based Orange Grove Bio inks first international partnerships with Korean universities, laying the foundation for its planned role as a bridge between the biotech industries in the two countries and to identify, develop and commercialize novel assets emerging from academic research.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.